Abstracts tagged "outcomes"

Abstract Number: 0803 • ACR Convergence 2021
Rheumatoid Arthritis Practice Performance (RAPP) Project at 6 Years: Population Medicine (POPMED) Principles and Treat to Target (T2T) Care Yield Dramatic Improvements in Both Outcomes and Access for RA Patients and Productivity for Rheumatologists
William Arnold¹, Erin Arnold¹, David Sikes², Gary Crump³, Kathleen Thomas⁴ and andrew johnson⁵, ¹Arnold Arthritis and Rheumatology, Wilmette, IL, ²Florida Medical Clinic, Wesley Chapel, FL, ³Rheumatology Associates, Louisville, KY, ⁴Community Health Network, Noblesville, IN, ⁵PopMed Solutions, Boyds, MD
Background/Purpose: The RAPP quality improvement project is a voluntary consortium of practicing rheumatologists founded in 2013 by Timothy Harrington MD, MACR. The primary focus is…
Abstract Number: 0884 • ACR Convergence 2021
Genetics of Longitudinal Disease Activity in Adults with Systemic Lupus Erythematosus
Linda Hiraki¹, Fangming Liao¹, Dafna Gladman², Ker-Ai Lee³, Zahi Touma⁴, Joan Wither⁵, Richard Cook³ and Murray Urowitz⁶, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³Department of Statistics and Actuarial Sciences, University of Waterloo, Waterloo, ON, Canada, ⁴University of Toronto, Mississauga, ON, Canada, ⁵University Health Network, Toronto, ON, Canada, ⁶Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada
Background/Purpose: Genetics and gene expression has been shown to correlate with systemic lupus erythematosus (SLE) disease severity. Our aim was to identify genetic risk loci…
Abstract Number: 1399 • ACR Convergence 2021
Validation of a Giant Cell Arteritis Probability Score
Charlie Oshinsky¹, Alison Bays¹, Ingeborg Sacksen², Elizabeth Jernberg³, Eugene zierler¹, Andreas Diamantopoulos⁴ and Scott Pollock¹, ¹University of Washington, Seattle, WA, ²University of Washington, Bellingham, WA, ³Virginia Mason Medical Center, Seattle, WA, ⁴Akerhus University Hospital, Brum, Norway
Background/Purpose: Giant cell arteritis (GCA) is the most common large vessel vasculitis. Failure to rapidly diagnose and treat patients with GCA can result in irreversible…
Abstract Number: 0418 • ACR Convergence 2021
Longitudinal Patterns of Renal Function in ANCA-Associated Vasculitis
Jennifer Hanberg¹, Xiaoqing Fu¹, Claire Cook², John Stone³, Hyon K. Choi⁴ and Zachary Wallace⁵, ¹Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Boston, MA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁴Massachusetts General Hospital, Lexington, MA, ⁵Massachusetts General Hospital, Newton, MA
Background/Purpose: Renal involvement is common in ANCA-associated vasculitis (AAV). Prior analyses show that end stage renal disease (ESRD) in AAV may be multifactorial. Little is…
Abstract Number: 038 • 2020 Pediatric Rheumatology Symposium
Change in Treatments and Outcomes After Implementation of a National Diagnosis and Treatment Guarantee Program for Juvenile Idiopathic Arthritis in Chile
Sara Concha¹, Pamela Morales ², Eduardo Talesnik ¹ and Arturo Borzutzky ¹, ¹Department of Infectious Diseases and Pediatric Immunology, School of Medicine, Pontificia Universidad Católica de Chile., Santiago, Chile, ²Department of Pediatric, Clinica Las Condes, Santiago, Chile
Background/Purpose: Juvenile idiopathic arthritis (JIA) is currently the most common childhood chronic rheumatic disease with high burden and socioeconomic costs for the patient’s family and…
Abstract Number: 067 • 2020 Pediatric Rheumatology Symposium
Response to Treatment with Intra-articular Triamcinolone Hexacetonide and Triamcinolone Acetonide in Oligo-articular Juvenile Idiopathic Arthritis
Rana Masoud¹, Wajiha Jeelani ², Barbine Agbor Agbor ³, Teresa Hennon ², Brian Wrotniak ⁴ and Rabheh Abdul Aziz ², ¹Department of Pediatrics, University at Buffalo, Oishei Children's Hospital, Buffalo, New York, ²Department of Pediatric Rheumatology, University at Buffalo, Oishei Children's Hospital, Buffalo, ³Department of Microbiology and Immunology, Jacobs School of Medicine and Biomedical Sciences, Buffalo, ⁴Department of Pediatrics, University at Buffalo, Oishei Children's Hospital, Buffalo, NY, USA, Buffalo
Background/Purpose: Oligo-articular juvenile idiopathic arthritis (Oligo JIA) is the most common subtype of juvenile idiopathic arthritis. Intra-articular corticosteroid (IAC) injection is a mainstay treatment of…
Abstract Number: 105 • 2020 Pediatric Rheumatology Symposium
Discovering the Implications of Adiposity in Juvenile Dermatomyositis
Vy Do¹, Chanhee Jo ², Jaclyn Albin ¹, Tracey Wright ¹, Julie Fuller ³ and Una Makris ¹, ¹UT Southwestern Medical Center, Dallas, ²Texas Scottish Rite Hospital, Dallas, ³UT Southwestern Medical Center, Frisco
Background/Purpose: Obesity and pro-inflammatory cytokines produced by adipocytes have been linked to many outcomes including disease severity, treatment response, and disease progression in several autoimmune…
Abstract Number: 109 • 2020 Pediatric Rheumatology Symposium
Incidence, Contributing Factors, and Impact of Diagnostic Delay in Juvenile Idiopathic Arthritis: Analysis of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Mei-Sing Ong¹, Gordon Schiff ² and Marc Natter ³ for the CARRA investigators, ¹Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, ²Harvard Medical School, Boston, ³Boston Children's Hospital, Boston
Background/Purpose: While early treatment of patients with newly diagnosed juvenile idiopathic arthritis (JIA) is an area of active study, delayed diagnosis of JIA is poorly…
Abstract Number: 118 • 2020 Pediatric Rheumatology Symposium
Long-Term Outcomes in Children Born to Anti-Ro and/or anti-La Positive Mothers
Talia Diaz¹, Daniela Dominguez ², Andrea Knight ³, Carl A. Laskin ⁴, Lawrence Ng ², Franklin Silverio ², Earl D. Silverman ⁵ and Linda Hiraki ⁶, ¹Division of Rheumatology, The Hospital for Sick Children, Toronto, Ontario, Canada, ²Division of Rheumatology, The Hospital for Sick Children, Toronto, Canada, ³SickKids Research Institute, Toronto, Canada, ⁴Mount Sinai Hospital and University of Toronto, Toronto, Canada, ⁵Division of Rheumatology, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Translational Medicine, Research Institute, The Hospital for Sick Children, Toronto, Canada, ⁶Division of Rheumatology, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, Toronto, Canada
Background/Purpose: Neonatal Lupus Erythematosus (NLE) is an acquired autoimmune disorder associated with the transplacental passage of maternal anti-Ro and/or anti-La antibodies. NLE manifestations include cardiac,…
Abstract Number: 125 • 2020 Pediatric Rheumatology Symposium
Feasibility and Pilot Study of Mental Health Screening in Juvenile Myositis
Kaveh Ardalan¹, Alison Manning ¹, Brian Feldman ², Gary Maslow ¹ and Andrea Knight ³, ¹Duke University Medical Center, Durham, ²The Hospital for Sick Children, Toronto, Canada, ³SickKids Research Institute, Toronto, Canada
Background/Purpose: Juvenile myositis (JM) negatively affects health-related quality of life due to chronic weakness, skin/muscle damage, multiorgan dysfunction, and side effects of immunosuppression. While JM’s…
Abstract Number: 133 • 2020 Pediatric Rheumatology Symposium
Pediatric Rheumatology Consultation for Both Traditional and Emerging Rheumatic Diseases in the Critical Care Setting
Jennifer Rammel¹, Kristen Staggers ², Satid Thammasitboon ², Jorge Coss Bu ², Amanda Brown ³ and Eyal Muscal ⁴, ¹Section of Nephrology and Rheumatology, Department of Pediatrics, University of Florida Health Jacksonville, Jacksonville, Florida, ²Baylor College of Medicine, Houston, Texas, ³Baylor College of Medicine, Houston, ⁴Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, houston
Background/Purpose: In addition to traditional rheumatic diseases (TRDs), Pediatric Rheumatologists are often consulted on emerging rheumatic diseases (ERDs) such as autoimmune encephalitis, seronegative vasculitides, and…
Abstract Number: 175 • 2020 Pediatric Rheumatology Symposium
Application of Juvenile Idiopathic Arthritis Treatment Guidelines and Factors Associated with Increased Likelihood of Intra-articular Corticosteroid Administration
Erin Balay¹, Jennifer Weiss ², Y. Ingrid Goh ³, Nathan Rubin ⁴ and Danielle Bullock ⁴, ¹University of Minnesota, saint paul, ²Hackensack University Medical Center, Hackensack, ³The Hospital for Sick Children, Toronto, Canada, ⁴University of Minnesota, Minneapolis
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a chronic childhood disease which can result in debilitating arthritis. The 2011 ACR JIA treatment guidelines recommend intra-articular corticosteroid…
Abstract Number: 177 • 2020 Pediatric Rheumatology Symposium
Educational Outcomes in a Young-Adult Cohort of Patients with Childhood Onset Systemic Lupus Erythematosus (SLE)
Anita Dhanrajani¹, Earl D. Silverman ², Andrea Knight ³, Deborah Levy ⁴ and Amanda Steiman ⁵, ¹Hospital for Sick Kids, Edmonton, Alberta, Canada, ²Division of Rheumatology, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Translational Medicine, Research Institute, The Hospital for Sick Children, Toronto, Canada, ³SickKids Research Institute, Toronto, Canada, ⁴Division of Rheumatology, The Hospital for Sick Children, Department of Pediatrics, University of Toronto, Toronto, Canada, ⁵Sinai Health System, Toronto, Ontario, Canada
Background/Purpose: The literature regarding educational and socioeconomic outcomes in young adults with childhood-onset Systemic Lupus Erythematosus (cSLE) are sparse. cSLE patients recently transitioned to adult…
Abstract Number: 333 • 2019 ACR/ARP Annual Meeting
Assessing the Relationship Between Gout and Return to Hemodialysis Among U.S. Renal Transplant Patients
Justin Li¹, David Yin ¹, Zheng Wang ¹, Mark Brigham ¹, Brian LaMoreaux ², Jeffrey Kent ², Megan Francis-Sedlak ², Richard Johnson ³, Nandini Hadker ¹ and Gavin Miyasato ¹, ¹Trinity Partners, Waltham, MA, ²Horizon Therapeutics plc, Lake Forest, IL, ³University of Colorado Denver, Aurora, CO
Background/Purpose: Although gout has been shown to be associated with poor renal outcomes among chronic kidney disease populations, this relationship is not well understood among…
Abstract Number: 869 • 2019 ACR/ARP Annual Meeting
Clinical Manifestations of Patients with Eosinophilic Granulomatosis with Polyangiitis in a Large North American Cohort
Irena Doubelt¹, David Cuthbertson ², Simon Carette ¹, Nader A. Khalidi ³, Curry L. Koening ⁴, Carol Langford ⁵, Carol A. McAlear ⁶, Larry W. Moreland ⁷, Paul Monach ⁸, Philip Seo ⁹, Ulrich Specks ¹⁰, Antoine Sreih ¹¹, Steven Ytterberg ¹⁰, Peter A. Merkel ¹², Christian Pagnoux ¹ and VCRC Vasculitis Clinical Research Consortium ¹³, ¹Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, ²University of South Florida, Tampa, FL, ³McMaster University, Hamilton, ON, Canada, ⁴University of Utah Hospital, Salt Lake City, UT, ⁵Cleveland Clinic, Cleveland, OH, ⁶University of Pennsylvania - VCRC Project Manager, Philadelphia, PA, ⁷University of Pittsburgh, Pittsburgh, PA, ⁸Brigham and Women's Hospital, Boston, MA, ⁹Johns Hopkins Medicine, Baltimore, MD, ¹⁰Mayo Clinic College of Medicine, Rochester, MN, ¹¹University of Pennsylvania, Philadelphia, PA, ¹²Univeristy of Pennsylvania, Philadelphia, PA, ¹³University of Pennsylvania, Division of Rheumatology, philadelphia
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare, systemic necrotizing small-vessel vasculitis, with only a few published North American series. This project aimed to…

1
2
3
…
10
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].